Wound Closure and Advanced Wound Care Global Market – Forecast To 2026
1 EXECUTIVE SUMMARY 26
2 INTRODUCTION 33
- 2.1 KEY TAKEAWAYS 33
- 2.2 SCOPE OF THE REPORT 34
- 2.3 REPORT DESCRIPTION 34
- 2.4 MARKETS COVERED 38
- 2.5 STAKEHOLDERS 41
- 2.6 RESEARCH METHODOLOGY 41
- 2.6.1 MARKET SIZE ESTIMATION 42
- 2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION 45
- 2.6.3 SECONDARY SOURCES 46
- 2.6.4 PRIMARY SOURCES 47
- 2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 48
- 2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 49
- 2.6.7 ASSUMPTIONS 50
3 MARKET ANALYSIS 51
- 3.1 INTRODUCTION 51
- 3.2 MARKET SEGMENTATION 53
- 3.3 FACTORS INFLUENCING MARKET 55
- 3.3.1 DRIVERS AND OPPORTUNITIES 56
- 3.3.1.1 Increasing prevalence of acute and chronic wounds 56
- 3.3.1.2 Increase in surgical procedural volume 57
- 3.3.1.3 Elevating demand for biologics in wound care 58
- 3.3.1.4 Emergence of technically advanced products 59
- 3.3.1.5 Increase in aging population and prevalence of lifestyle diseases 61
- 3.3.1.6 Acquisitions to open an array of opportunities for the market to flourish 62
- 3.3.2 RESTRAINTS AND THREATS 62
- 3.3.2.1 Lack of professionals in handling the sophisticated advanced wound closure and wound care techniques 62
- 3.3.2.2 High cost of advanced wound closure and wound care devices 63
- 3.3.2.3 Adverse effects of wound closure and wound care devices 64
- 3.3.2.4 Unfavorable reimbursement policies in developing nations 65
- 3.3.2.5 Stringent regulatory bodies guiding the wound closure and advanced wound care manufacturers 66
- 3.3.2.6 Increasing preference for minimally invasive surgeries 67
- 3.3.1 DRIVERS AND OPPORTUNITIES 56
- 3.4 REGULATORY AFFAIRS 68
- 3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION 68
- 3.4.1.1 ISO 9001: 2015 quality management system 68
- 3.4.1.2 ISO 13485 medical devices 68
- 3.4.1.3 ISO 10993 biological evaluation of medical devices 69
- 3.4.1.4 ISO 14971 risk management of medical devices 69
- 3.4.1.5 IEC 60601-1 medical electrical equipment standard 70
- 3.4.1.6 IEC 60601-1-11 home care safety 70
- 3.4.2 ASTM INTERNATIONAL STANDARDS 70
- 3.4.3 U.S. 70
- 3.4.4 CANADA 72
- 3.4.5 EUROPE 73
- 3.4.6 JAPAN 74
- 3.4.7 CHINA 75
- 3.4.8 INDIA 76
- 3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION 68
- 3.5 CLINICAL TRIALS 78
- 3.6 TECHNOLOGICAL ADVANCEMENTS 80
- 3.6.1 NANOPARTICLE BASED WOUND HEALING 80
- 3.6.2 SMART WOUND DRESSINGS 80
- 3.6.3 GENE THERAPY 81
- 3.6.4 3D BIOINK PRINTER 81
- 3.6.5 BIOACTIVE GLASSES IN WOUND REPAIR 81
- 3.6.6 STEM CELL TECHNOLOGY 82
- 3.6.7 BIOCHIPS FOR WOUND HEALING 82
- 3.6.8 MICRO ANCHOR TECHNOLOGY 82
- 3.7 PORTER’S FIVE FORCE ANALYSIS 83
- 3.7.1 THREAT OF NEW ENTRANTS 84
- 3.7.2 THREAT OF SUBSTITUTES 85
- 3.7.3 BARGAINING POWER OF SUPPLIERS 86
- 3.7.4 BARGAINING POWER OF BUYERS 86
- 3.7.5 COMPETITIVE RIVALRY 87
- 3.8 SUPPLY CHAIN ANALYSIS 88
- 3.9 REIMBURSEMENT SCENARIO 92
- 3.10 FUNDING SCENARIO 95
- 3.11 BIOMATERIALS 98
- 3.12 SINGLE USE V/S REUSABLE DEVICES 104
- 3.13 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 107
- 3.13.1 WOUND CLOSURE AND ADVANCED WOUND CARE GLOBAL MARKET SHARE ANALYSIS 107
- 3.13.2 SEALANTS, ADHESIVES AND HEMOSTATS GLOBAL MARKET SHARE ANALYSIS 110
- 3.13.3 ADVANCED WOUND DRESSINGS GLOBAL MARKET SHARE ANALYSIS 113
- 3.13.4 NEGATIVE PRESSURE WOUND THERAPY (NPWT) GLOBAL MARKET SHARE ANALYSIS 116
- 3.13.5 ENGINEERED SKIN SUBSTITUTES AND BIOLOGICS GLOBAL MARKET SHARE ANALYSIS 119
- 3.14 WOUND CLOSURE AND ADVANCED WOUND CARE COMPANY COMPARISON TABLE BY PRODUCT TYPE, PRODUCT NAME AND APPLICATION 122
- 3.14.1 WOUND CLOSURE DEVICES 122
- 3.14.2 SEALANTS, ADHESIVES AND HAEMOSTATS 126
- 3.14.3 WOUND CARE DEVICES 131
- 3.14.4 BIOLOGICS AND ADVANCED WOUND DRESSINGS 134
4 WOUND CLOSURE AND ADVANCED WOUND CARE GLOBAL MARKET, BY WOUND TYPE 144
- 4.1 INTRODUCTION 144
- 4.2 ACUTE WOUND 147
- 4.3 CHRONIC WOUND 149
5 WOUND CLOSURE AND ADVANCED WOUND CARE GLOBAL MARKET, BY PRODUCT 151
- 5.1 INTRODUCTION 151
- 5.2 WOUND CLOSURE AND WOUND CARE DEVICES 155
- 5.2.1 SUTURES 160
- 5.2.1.1 Sutures by operational mode 163
- 5.2.1.1.1 Manual sutures 166
- 5.2.1.1.2 Automated suturing devices 168
- 5.2.1.2 Sutures by material type 170
- 5.2.1.2.1 Absorbable sutures 173
- 5.2.1.2.2 Non-absorbable sutures 175
- 5.2.2 WOUND CLOSURE STRIPS 178
- 5.2.3 STAPLES 180
- 5.2.4 LIGATING CLIPS 182
- 5.2.5 NEGATIVE PRESSURE WOUND THERAPY (NPWT) 184
- 5.2.6 HYPERBARIC OXYGEN THERAPY (HOT) 186
- 5.2.7 ENERGY BASED DEVICES 189
- 5.3 ADVANCED WOUND CLOSURE AND BIOLOGICS 193
- 5.3.1 SEALANTS AND ADHESIVES 197
- 5.3.1.1 Natural sealants and adhesives 201
- 5.3.1.1.1 Collagen sealants and adhesives 205
- 5.3.1.1.2 Albumin sealants and adhesives 207
- 5.3.1.1.3 Gelatin sealants and adhesives 209
- 5.3.1.1.4 Fibrin sealants and adhesives 211
- 5.3.1.1.5 Other natural sealants and adhesives 213
- 5.3.1.2 Synthetic sealants and adhesives 215
- 5.3.1.2.1 Cyanoacrylate sealants and adhesives 219
- 5.3.1.2.2 Hydrogels sealants and adhesives 221
- 5.3.1.2.3 Other synthetic sealants and adhesives 224
- 5.3.2 HAEMOSTATS 226
- 5.3.2.1 MECHANICAL HAEMOSTATS 230
- 5.3.2.2 ACTIVE HAEMOSTATS 232
- 5.3.2.3 FLOWABLE HAEMOSTATS 234
- 5.3.2.4 FIBRIN HAEMOSTATS 236
- 5.3.3 ENGINEERED SKIN SUBSTITUTES 238
- 5.3.4 GROWTH FACTORS 241
- 5.4 ADVANCED WOUND DRESSING 243
- 5.4.1 FOAM DRESSING 247
- 5.4.2 HYDROCOLLOID DRESSING 249
- 5.4.3 FILM DRESSING 251
- 5.4.4 ANTIMICROBIAL DRESSING 253
- 5.4.5 HYDROGEL DRESSING 255
- 5.4.6 OTHER ADVANCED WOUND DRESSING 257
6 WOUND CLOSURE AND ADVANCED WOUND CARE GLOBAL MARKET, BY APPLICATION 260
- 6.1 INTRODUCTION 260
- 6.2 BURNS 263
- 6.3 ULCERS 265
- 6.3.1 PRESSURE ULCERS 269
- 6.3.2 VENOUS LEG ULCERS 271
- 6.3.3 DIABETIC FOOT ULCERS 273
- 6.3.4 ARTERIAL ULCERS 276
- 6.4 SURGICAL WOUNDS 278
- 6.5 TRAUMATIC LACERATIONS 282
- 6.6 RADIONECROSIS 284
7 WOUND CLOSURE AND ADVANCED WOUND CARE GLOBAL MARKET, BY END-USER 286
- 7.1 INTRODUCTION 286
- 7.2 HOSPITALS AND ASC 289
- 7.3 CLINICS AND COMMUNITY HEALTHCARE SERVICES 292
- 7.4 OTHER END-USER 295
8 REGIONAL ANALYSIS 297
- 8.1 INTRODUCTION 297
- 8.2 NORTH AMERICA 301
- 8.2.1 U.S. 326
- 8.2.2 REST OF NORTH AMERICA 330
- 8.3 EUROPE 335
- 8.3.1 GERMANY 360
- 8.3.2 U.K. 364
- 8.3.3 FRANCE 369
- 8.3.4 REST OF EUROPE 372
- 8.4 APAC 377
- 8.4.1 JAPAN 402
- 8.4.2 CHINA 405
- 8.4.3 INDIA 409
- 8.4.4 REST OF APAC 414
- 8.5 ROW 418
- 8.5.1 BRAZIL 443
- 8.5.2 REST OF LATAM 446
- 8.5.3 MIDDLE EAST AND AFRICA 449
9 COMPETITIVE LANDSCAPE 453
- 9.1 INTRODUCTION 453
- 9.2 PRODUCT LAUNCH 454
- 9.3 ACQUISITION 458
- 9.4 PRODUCT APPROVAL 460
- 9.5 PARTNERSHIPS AND EXPANSIONS 462
- 9.6 OTHERS 463
10 MAJOR COMPANIES 466
- 10.1 3M COMPANY 466
- 10.1.1 OVERVIEW 466
- 10.1.2 FINANCIALS 467
- 10.1.3 PRODUCT PORTFOLIO 471
- 10.1.4 KEY DEVELOPMENTS 472
- 10.1.5 BUSINESS STRATEGY 472
- 10.1.6 SWOT ANALYSIS 473
- 10.2 BAXTER INTERNATIONAL, INC. 474
- 10.2.1 OVERVIEW 474
- 10.2.2 FINANCIALS 475
- 10.2.3 PRODUCT PORTFOLIO 478
- 10.2.4 KEY DEVELOPMENTS 479
- 10.2.5 BUSINESS STRATEGY 481
- 10.2.6 SWOT ANALYSIS 482
- 10.3 B. BRAUN MELSUNGEN AG 483
- 10.3.1 OVERVIEW 483
- 10.3.2 FINANCIALS 484
- 10.3.3 PRODUCT PORTFOLIO 487
- 10.3.4 KEY DEVELOPMENTS 488
- 10.3.5 BUSINESS STRATEGY 488
- 10.3.6 SWOT ANALYSIS 489
- 10.4 CARDINAL HEALTH INC. 490
- 10.4.1 OVERVIEW 490
- 10.4.2 FINANCIALS 491
- 10.4.3 PRODUCT PORTFOLIO 495
- 10.4.4 KEY DEVELOPMENTS 496
- 10.4.5 BUSINESS STRATEGY 497
- 10.4.6 SWOT ANALYSIS 498
- 10.5 COLOPLAST GROUP 499
- 10.5.1 OVERVIEW 499
- 10.5.2 FINANCIALS 500
- 10.5.3 PRODUCT PORTFOLIO 503
- 10.5.4 KEY DEVELOPMENTS 503
- 10.5.5 BUSINESS STRATEGY 504
- 10.5.6 SWOT ANALYSIS 505
- 10.6 CONVATEC INC. 506
- 10.6.1 OVERVIEW 506
- 10.6.2 FINANCIALS 507
- 10.6.3 PRODUCT PORTFOLIO 510
- 10.6.4 KEY DEVELOPMENTS 511
- 10.6.5 BUSINESS STRATEGY 512
- 10.6.6 SWOT ANALYSIS 513
- 10.7 INTEGRA LIFESCIENCES HOLDINGS CORPORATION 514
- 10.7.1 OVERVIEW 514
- 10.7.2 FINANCIALS 515
- 10.7.3 PRODUCT PORTFOLIO 519
- 10.7.4 KEY DEVELOPMENTS 520
- 10.7.5 BUSINESS STRATEGY 521
- 10.7.6 SWOT ANALYSIS 522
- 10.8 JOHNSON & JOHNSON (ETHICON) 523
- 10.8.1 OVERVIEW 523
- 10.8.2 FINANCIALS 524
- 10.8.3 PRODUCT PORTFOLIO 528
- 10.8.4 KEY DEVELOPMENTS 529
- 10.8.5 BUSINESS STRATEGY 531
- 10.8.6 SWOT ANALYSIS 532
- 10.9 MEDTRONIC PUBLIC LIMITED COMPANY 533
- 10.9.1 OVERVIEW 533
- 10.9.2 FINANCIALS 534
- 10.9.3 PRODUCT PORTFOLIO 539
- 10.9.4 KEY DEVELOPMENTS 541
- 10.9.5 BUSINESS STRATEGY 541
- 10.9.6 SWOT ANALYSIS 542
- 10.10 MOLNLYCKE HOLDING AB 543
- 10.10.1 OVERVIEW 543
- 10.10.2 FINANCIALS 544
- 10.10.3 PRODUCT PORTFOLIO 547
- 10.10.4 KEY DEVELOPMENTS 548
- 10.10.5 BUSINESS STRATEGY 549
- 10.10.6 SWOT ANALYSIS 550
- 10.11 PAUL HARTMANN AG 551
- 10.11.1 OVERVIEW 551
- 10.11.2 FINANCIALS 552
- 10.11.3 PRODUCT PORTFOLIO 555
- 10.11.4 KEY DEVELOPMENTS 556
- 10.11.5 BUSINESS STRATEGY 556
- 10.11.6 SWOT ANALYSIS 557
- 10.12 SMITH & NEPHEW PLC 558
- 10.12.1 OVERVIEW 558
- 10.12.2 FINANCIALS 559
- 10.12.3 PRODUCT PORTFOLIO 563
- 10.12.4 KEY DEVELOPMENTS 563
- 10.12.5 BUSINESS STRATEGY 565
- 5.3.1 SEALANTS AND ADHESIVES 197
- 5.2.1 SUTURES 160
Wound closure and advanced wound care consists of the use of various therapeutic interventional devices to efficiently and economically close and heal a wound by integrating established wound healing concepts with the dynamic technological changes and resources. Compared to traditional wound closure and wound care products, the current wound management products assure patients and healthcare providers with improved efficacy, effectiveness and faster healing of the wounds in a non-invasive and aesthetically appealing manner. Increased utilization of the various wound management products for the numerous and varied types of wounds among the patients, elevating inclination of the value-centric global patient pool towards the technologically advanced wound management products with better therapeutic outcomes and the need to reduce hospitalization duration and ease the patient’s condition through faster wound closure and accelerated wound healing time are fuelling the wound closure and advanced wound care global market.
As estimated by IQ4I Research, the wound closure and advanced wound care global market is expected to reach $25,527.8 million by 2026 growing at a mid single digit CAGR from 2019 to 2026, due to increasing prevalence of acute and chronic wounds, escalating number of surgical procedures associated with highly prevalent lifestyle and chronic diseases, rapidly increasing geriatric population, increasing demand for highly efficient, scarless and sophisticated wound management products from the value-centric patient population, increasing R&D spending for developing innovative and technologically advanced products, growing economies and increasing demand for better healthcare facilities in emerging markets. The wound closure and advanced wound care market is segmented by wound type, product, application, end-user and geography.
Based on the wound type, the wound closure and advanced wound care global market is segmented into Acute wound and Chronic wound. Acute wound segment accounted for the largest revenue in 2019 and is expected to growing at a mid single digit CAGR from 2019 to 2026. Chronic wound segment is expected to growing at a mid single digit CAGR from 2019 to 2026.
Based on the product type, the wound closure and advanced wound care global market is segmented into Wound closure & wound care devices, Advanced wound closure & Biologics and Advanced wound dressings. Among these products, wound closure & wound care devices segment is the largest and fastest-growing product segment and is expected to grow at a mid single digit CAGR from 2019 to 2026.
Among the wound closure and wound care devices, sutures segment accounted for the largest revenue in 2019 due to their highly efficient and more accurate wound closure mechanism. Staples segment is the fastest emerging segment growing at a high single digit CAGR from 2019 to 2026 as their use is associated with strong, quick wound closure with minimal tissue reactions. In the sutures global market by operational mode, manual operated sutures or manual sutures represented the largest product segment in 2019, while automated suturing devices are expected to grow at a high single digit CAGR during the forecasted period. Among the overall sutures market by type, the absorbable sutures holds the largest share in 2019 and is expected to grow at a mid single digit CAGR from 2019 to 2026.
Among the advanced wound closure and biologics, hemostats segment accounted for the largest revenue in 2019 due to their efficiency in rapid cessation of blood loss and swift wound closure. Engineered skin substitutes segment is the fastest emerging segment growing at a high single digit CAGR from 2019 to 2026 mainly due to their assurance of non-invasive wound management with better therapeutic patient outcomes. Based on the source, sealants and adhesives market has been classified as natural and synthetic sealants & adhesives. The natural sealants and adhesives segment commanded the largest revenue in 2019 and is expected to grow at a mid single digit CAGR during the forecasted period. In the natural sealants and adhesives global market by product type, fibrin sealants and adhesives segment accounted for the largest revenue in 2019 and is expected to grow at a mid single digit CAGR from 2019 to 2026, while gelatin sealants and adhesives segment is the fastest emerging segment growing at a mid single digit CAGR from 2019 to 2026. Among the various synthetic sealants and adhesives by product type, cyanoacrylate sealants and adhesives segment accounted for the largest revenue in 2019 and is expected to grow at a low single digit CAGR from 2019 to 2026. In hemostats global market by type, mechanical hemostats segment accounted for the largest revenue in 2019 and is expected to grow at a mid single digit CAGR from 2019 to 2026, while fibrin hemostats segment is the fastest emerging segment growing at a high single digit CAGR from 2019 to 2026.
Among the advanced wound dressings, foam dressings segment accounted for the largest revenue in 2019 and is expected to grow at a mid single digit CAGR during the forecasted period owing to the development of various innovative and highly comfortable foam dressings for treating the most chronic wounds.
Based on the application, the wound closure and advanced wound care global market is segmented into Burns, Ulcers, Surgical wounds, Trauma lacerations and Radionecrosis. Among these, surgical wounds segment accounted for the largest revenue in 2019 and is expected to growing at a mid single digit CAGR from 2019 to 2026. Ulcers segment is the fastest-growing segment growing at a mid single digit CAGR from 2019 to 2026 due to the elevating ulcer and chronic disease burden among the global population and the emergence of large number of technologically advanced, innovative products for ulcer management. In the ulcer global market by application type, diabetic foot ulcers segment accounted for the largest revenue in 2019 and is expected to grow at a mid single digit CAGR from 2019 to 2026.
Based on the end-user, the wound closure and advanced wound care global market is segmented into Hospitals and Ambulatory Surgery Centers (ASCs), Clinics & Community Healthcare Services and Others (Home healthcare settings and Research Institutes). Among these, Hospitals and Ambulatory Surgery Centers (ASCs) segment accounted for the largest revenue in 2019 and is expected to growing at a mid single digit CAGR from 2019 to 2026.
Based on the region, the wound closure and advanced wound care global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, U.K and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of APAC) and Rest of the world (Brazil, Rest of Latin America and Middle East & Africa). North America accounted for the largest revenue in 2019 and is expected to growing at a mid single digit CAGR from 2019 to 2026 due to increasing adoption of advanced wound management products for the closure and accelerated healing of the highly prevalent acute and chronic wounds in the region, escalating geriatric population and increasing demand for highly efficient, scarless and sophisticated wound management products from the value-centric patient population, increasing number of researches for the development of innovative and technologically advanced products and substantial insurance coverage for wound management products.
The Asia-Pacific is the fastest-growing region in wound closure and advanced wound care market in 2019 and is expected to growing at a high single digit CAGR from 2019 to 2026 due to elevating acute and chronic wounds burden in the region, escalating number of surgical procedures associated with highly prevalent chronic diseases, increasing geriatric population, increasing demand for better healthcare facilities, increasing penetration of reimbursement schemes in developing countries, elevating demand for better healthcare facilities from the population in the region, growing economies of the region, availability of various kinds of wound management products and increasing patient awareness of these products and increasing medical tourism prospects of the region.
The wound closure and advanced wound care global market is fragmented without a dominant major player in the market that offers lots of opportunities for low barrier entry for small and medium-sized companies with distinct products in the market. Some of the major players in wound closure and advanced wound care market include Medtronic PLC (Ireland), 3M Company (U.S.), Smith & Nephew PLC (U.K.), Johnson & Johnson (J&J) (U.S.), Baxter International Inc. (U.S.), Molnlycke Holding AB (Sweden), Convatec Inc. (U.K.), Paul Hartmann AG (Germany), Integra LifeSciences Corporation (U.S.), Cardinal Health Inc. (U.S.), B. Braun Melsungen AG (Germany), Coloplast Group (Denmark) and others.
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
• North America
o U.S.
o Rest of North America
• Europe
o Germany
o U.K.
o France
o Rest of Europe
• Asia-Pacific
o Japan
o China
o Indian
o Rest of APAC
• Rest of the World (RoW)
o Brazil
o Rest of LATAM
o Middle East and Africa